Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1600-0609.1992.tb01811.x | DOI Listing |
BMC Pediatr
January 2025
Department of Pediatrics, Center of Pediatric Nephrology and Transplantation (CPNT), Kasr Al Ainy Faculty of Medicine, Cairo University, Cairo, Egypt.
Background: Anemia is prevalent among pediatric patients diagnosed with end-stage kidney disease (ESKD). In addition, erythropoiesis-stimulating agents (ESA) and iron supplementation are considered the cornerstones in the management of anemia. However, a significant proportion of patients remain anemic.
View Article and Find Full Text PDFInt J Nephrol Renovasc Dis
January 2025
Astellas Pharma Singapore Pte. Ltd, Singapore, Singapore.
Introduction: Limited data exist regarding treatment patterns and symptom burden of patients with anemia of chronic kidney disease (CKD) in the Middle East, South Africa, and Türkiye.
Methods: This real-world study explored clinical characteristics, symptom burden, and treatment patterns of patients with anemia of CKD living in the Middle East, South Africa, and Türkiye. Physician and patient perceptions of treatment were captured via cross-sectional surveys; patients' clinical characteristics were recorded by retrospective review of medical records.
Medicine (Baltimore)
November 2024
Graduate School, Heilongjiang University of Chinese Medicine, Haerbin, China.
The journey of bone repair is a lengthy process. Traditionally, oral or topical medications have been employed to facilitate healing, approaches that are not only costly but may also lead to adverse effects such as gastrointestinal damage. With advancements in electrophysiology, the significance of bioelectric activity in tissue repair has become increasingly prominent, thereby enhancing the focus on research into electroacupuncture (EA) for bone repair.
View Article and Find Full Text PDFBiomedicines
December 2024
Division of Gastroenterology and Nephrology, Faculty of Medicine, Tottori University, Nishi-cho 36-1, Yonago 683-8504, Tottori, Japan.
Background/objectives: Renal anemia is one of the major complications associated with chronic kidney disease (CKD). Erythropoietin-stimulating agents (ESAs) are commonly used; however, some patients exhibit resistance. Hypoxia-inducible factor prolyl-hydroxylase inhibitors (HIF-PHIs) have emerged as a novel treatment for renal anemia, enhancing erythropoiesis and iron metabolism.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!